期刊文献+

血清胸苷激酶1对胃肠癌患者的诊断价值

下载PDF
导出
摘要 目的:探讨血清胸苷激酶1(TK1)对胃肠癌患者的诊断价值。方法:应用免疫印迹增强化学发光方法,检测59例胃肠癌患者和32名健康体检者血清TK1(sTK1)浓度;分析该方法的灵敏度,并比较sTK1在两种人群中的差异。结果:胃肠癌患者和健康体检者sTK1值分别为2.07±1.14pmoL/L和0.88±0.64pmoL/L,前者sTK1水平显著高于后者(P<0.01)。胃肠癌患者和健康体检者sTK1阳性率分别为54.24%和6.25%,前者阳性率显著高于后者(P<0.01)。sTK1测定灵敏度为54.24%,特异度为93.75%,诊断符合率为68.13%。ROC曲线分析,曲线下面积为0.792,95%可信区间为(0.700,0.884)。结论:sTK1测定值对胃肠道肿瘤具有较好的诊断价值。
作者 沈丽莎 孔俊
出处 《中国社区医师(医学专业)》 2011年第26期214-215,共2页
  • 相关文献

参考文献7

  • 1Munch-Petersen B.Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2:a mini review[J].Nucleosides Nucleotides Nucleic Acids,2010,29(4-6):363-369.
  • 2He Q,Skog S,Wang N,et al.characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase,which is a marker for cell proliferation[J].Eur J C Biol,1996,70(2):117-124.
  • 3Weissman SM,Smellie RMS,Paul J.Studies on the biosynthesis of deoxyribonucleic acid by extracts of mammalian cells.IV The phosphorylation of thymidine[J].Biochim Biophys Acta,1960,45:101-110.
  • 4He Q,Fornander T,Johansson H,et al.Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer[J].Anticancer Res,2006,26(6C):4753-4759.
  • 5李清茹,桑士标,袁航,苏成海,吴翼伟,张旻,周际,Ellen He,Sven Skog,赵久涛.血清胸苷激酶1检测对恶性肿瘤诊断及疗效评估的意义[J].中华核医学杂志,2009,29(4):271-273. 被引量:16
  • 6Zhang J,Jia Q,Zou S,et al.Thymidino kinasel:a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients[J].Oncol Rep,2006,15(2):455-461.
  • 7顾光大.血清胃蛋白酶原、胸苷激酶联合检测对胃癌的诊断意义[J].实用医学杂志,2009,25(5):715-717. 被引量:14

二级参考文献16

  • 1吕晓娴,刘冰,张瑞丽.血清CEA和CA199及CA724联合检测对胃癌诊断的临床意义[J].中国肿瘤临床与康复,2007,14(1):26-28. 被引量:30
  • 2刘家云,陈名声,苏明权,于文彬,郝晓柯.血清胃蛋白酶原、促胃液素对胃癌的诊断价值[J].现代检验医学杂志,2007,22(3):19-21. 被引量:8
  • 3Ulmert D, Cronin AM, Bjork Th, et al. Prostatic-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case control study. BMC Med, 2008, 6, 1-22.
  • 4Li HX, Lei DS, Wang XQ, et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep, 2005,13 : 145-149.
  • 5He Q, Zhzalg P, Zou L, et al. Concentration of thymidine kinase 1 in serum ( S-TK1 ) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep, 2005, 14: 1013- 1019.
  • 6Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1 : a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep, 2006, 15 : 455-461.
  • 7He Q, Fomander T, Johansson H, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res, 2006, 26 : 4753-4759.
  • 8Wu C, Yang R, Zhou J, et al. Production and characterisation of a novel chicken IgY antibody raised against C-temainal peptide from human thymidine kinase 1. J Immunol Methods, 2003, 277: 157- 169.
  • 9Chen Z, Zhou H, Li S, et al. Serological thymidine kinase 1 ( STK1 ) indicates an elevated risk for the development of malignant tumours. Anticaner Res, 2008, 28: 3897-3907.
  • 10He Q, Wang N, Skog S, et al. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol, 1996, 70: 117-124.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部